EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Excelsior Biopharma (6496) fair value: what the stock is really worth

As of Oct 8, 2026: fair value of Excelsior Biopharma TWD 31.80, price TWD 23.85, upside +33.3%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0006496003

EB Thin data Oct 3, 2026

Excelsior Biopharma

6496 · TWO

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value 31.80 TWD · Undervalued (+33.3%)
Low debt
Quality 42/100
Weak Growth (revenue 5y −9.1 %/yr in TWD)
Loss-making · -22.1% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 12/100
Thin data
Watch Excelsior Biopharma for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

36.50 TWD 22.85 TWD Fair Value 31.80 TWD May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 22.85 TWD – 36.50 TWD · fair‑value band 20.99 TWD – 39.74 TWD · the 23.85 TWD price screens below the 31.80 TWD fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Excelsior Biopharma in your weekly email

Every Wednesday you see whether Excelsior Biopharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally.

Show more

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importing and exporting of active pharmaceutical ingredients, food, and cosmeceuticals; development of cosmetics; research, importing and exporting of technologies; and pharmaceutical technologies transfer. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was founded in 1986 and is headquartered in Taipei, Taiwan.

Stock analysis

Excelsior Biopharma (6496) currently trades at 23.85 TWD, while our model-based Fair Value estimate is 31.80 TWD, implying the stock looks roughly 25.0% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 20.99 TWD (bear) to 39.74 TWD (bull), the price of 23.85 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Excelsior Biopharma reported revenue of 898M TWD in FY2025 versus 1.3B TWD in FY2021, a compound −9.5%/yr. Reported net income was −183M TWD in FY2025.

Key figures

Market cap 1.1B TWD (≈ $34.8M) · P/S ratio 1.19 · EPS (TTM) −4.46 TWD · Net margin −20.4% · Return on equity −26.1% · Return on assets (EBIT) −4.6% · Operating margin −26.2% · Revenue (TTM) 937M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 21% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at 33%, 6496 screens cheaper than that median.

Fair Value models

Bear 20.99 TWD Fair Value 31.80 TWD Bull 39.74 TWD
Price 23.85 TWD · Upside +33.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 8.65 TWD 11.59 TWD 17.31 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 8.65 TWD 11.59 TWD 17.31 TWD 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

Of which business quality 42 · Market factors (momentum, volatility) 43

Profitability 17
Margins and returns on capital today
Quality Growth 24
Are margins and returns improving?
Cashflow 6
Earnings quality: real cash, not paper profit
Fin. Strength 55
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 90
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 13
Distance to the 52-week high (market factor)
Net Issuance 87
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.2% (2020) → −19.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 6496, get fair value alerts →

Compare Excelsior Biopharma with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 571 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside +33.3% · Top 25%
Profitability
Return on assets −8.8% · Bottom 25%
Net margin (TTM) −22.1% · Bottom 25%
Operating margin (TTM) −26.2% · Bottom 25%
Growth and dividend
Revenue growth 15.1% · Above median
Balance sheet
Debt / equity 0.14× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/S (TTM) 0.04× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)78 · sector 16
FUTURE (revenue growth)76 · sector 25
PAST (return on equity)0 · sector 28
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $69.69 $110.50 +59% vs 6496
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10% vs 6496
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7% vs 6496
Haleon plc HLN $9.26 $8.49 −8% vs 6496
Merck KGaA MRK €140.15 €108.94 −22% vs 6496
Galderma Group GALD CHF 163.00 CHF 110.32 −32% vs 6496
Takeda Pharmaceutical Company TAK $17.86 $11.35 −36% vs 6496
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43% vs 6496
Teva Pharmaceutical Industries Limited TEVA $39.18 $20.88 −47% vs 6496
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81% vs 6496

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Excelsior Biopharma · Fair Value
31.80 TWD +25%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Excelsior Biopharma Fair Value". https://www.fairvalue-calculator.com/stock/6496

Frequently asked questions

Is Excelsior Biopharma (6496) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 31.80 TWD versus a price of 23.85 TWD, about +33% upside (undervalued).
What is the fair value of 6496?
Our model-based fair value for Excelsior Biopharma is 31.80 TWD (as of Oct 3, 2026), built from audited fundamentals. The current price: 23.85 TWD.
What is the quality score of 6496?
Excelsior Biopharma has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Excelsior Biopharma (6496)?
Our model-based price target is the fair value of 31.80 TWD (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 20.99 TWD, optimistic scenario 39.74 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Excelsior Biopharma stock forecast for 2026?
Our models put fair value at 31.80 TWD, about +33% upside versus a price of 23.85 TWD (undervalued). Cautious scenario 20.99 TWD, optimistic scenario 39.74 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Excelsior Biopharma (6496)?
Excelsior Biopharma reported trailing-twelve-month revenue of about 937M TWD (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Excelsior Biopharma (6496)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Excelsior Biopharma it is 31.80 TWD per share (as of Oct 3, 2026), against a price of 23.85 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Excelsior Biopharma stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 6496 trades below its calculated fair value: price 23.85 TWD, fair value 31.80 TWD, a gap of about +33% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6496?
No. The price is what the market pays today (23.85 TWD); the fair value is what the company's own numbers justify (31.80 TWD). For Excelsior Biopharma the two are 7.95 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Excelsior Biopharma worth?
The market values Excelsior Biopharma at about 1.1B TWD (market capitalisation, as of Oct 3, 2026). Per share that is 23.85 TWD; our models calculate a fair value of 31.80 TWD per share.
What do the bullish and bearish scenarios say about 6496?
Our models span a range for Excelsior Biopharma: cautious scenario 20.99 TWD, base 31.80 TWD, optimistic 39.74 TWD per share (as of Oct 3, 2026, price 23.85 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Excelsior Biopharma (6496)?
Balance-sheet figures for Excelsior Biopharma (as of Oct 3, 2026): return on equity −26.1%, debt of 0.14 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 6496 from its 52-week high?
Excelsior Biopharma trades at 23.85 TWD, about 21% below its 52-week high of 30.10 TWD and 4% above the low of 22.85 TWD (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of 31.80 TWD is for.
Which stocks are comparable to Excelsior Biopharma?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Excelsior Biopharma stock attractive at the current price?
The data as of Oct 3, 2026: price 23.85 TWD, calculated fair value 31.80 TWD (+33%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6496 calculated?
We run Excelsior Biopharma through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 31.80 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.6 % above its aggregate fair value. Excelsior Biopharma currently trades 25 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Excelsior Biopharma (6496)?
The closing price on Oct 8, 2026 was 23.85 TWD. Our model-based fair value is 31.80 TWD, about +33% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Excelsior Biopharma right now?
The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (20.99 TWD to 39.74 TWD) leaves room in how you read the outcome.

Key figures of Excelsior Biopharma

How large is the market capitalisation of Excelsior Biopharma (6496)?
The market capitalisation of Excelsior Biopharma is 1.1B TWD (≈ $34.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Excelsior Biopharma (6496)?
The price-to-sales ratio of Excelsior Biopharma is 1.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Excelsior Biopharma (6496)?
Earnings per share at Excelsior Biopharma are −4.46 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Excelsior Biopharma (6496)?
The net margin of Excelsior Biopharma is −20.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Excelsior Biopharma (6496)?
The return on equity (ROE) of Excelsior Biopharma is −26.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Excelsior Biopharma (6496)?
On an EBIT basis the return on assets of Excelsior Biopharma is −4.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Excelsior Biopharma (6496)?
The operating margin of Excelsior Biopharma is −26.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Excelsior Biopharma (6496)?
Revenue at Excelsior Biopharma is growing +15.1% versus a year earlier (3y avg +10.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Excelsior Biopharma (6496)?
Earnings per share at Excelsior Biopharma are growing −79.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Excelsior Biopharma (6496) generate?
The free cash flow of Excelsior Biopharma is −176M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Excelsior Biopharma (6496) carry?
The net debt of Excelsior Biopharma is 106M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Excelsior Biopharma in the live analysis

One click puts Excelsior Biopharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.